PROJECT

Projects

Environmental & Social Review Summary

Project Number

49792

Company Name

PT Etana Biotechnologies Indonesia

Date ESRS Disclosed

May 13, 2025

Country

Indonesia

Region

East Asia and the Pacific

Last Updated Date

Jul 4, 2025

Environmental Category

B - Limited

Status

Pending Signing

Previous Events

Approved : Jul 3, 2025

Sector

other

Industry

other

Department

Regional Industry - MAS Asia & Pac

Project Description

 IFC’s proposed investment is an equity investment of up to US$30m equivalent in PT Etana Biotechnologies Indonesia (“Etana” or the “Company”) https://www.id.etanabiotech.com/news, an emerging Indonesian biopharmaceutical company with product range in the areas of oncology, nephrology, metabolic and infectious diseases.

 

Etana production facility is located in Kawasan Industry Pulogadung, Cakung, East Jakarta. The Company currently has more than forty registered products and plans to roll out multiple products and scale up its operations. The company’s expansion plan prioritizes fully utilizing the existing drug substance production facility by installing additional production and quality control equipment and building a new warehouse. Subsequently, the Company will build another Drug Substance production facility on the existing site. At the time of IFC appraisal, the establishment of additional drug substance facilities is still at concept stage, with construction works expected to commence in 2026. 

Overview of IFC's Scope of Review

  The review of this project involved appraising environmental, health and safety (EHS) and social-related policies, procedures, and information submitted by the company. IFC also met with Etana’s senior management, E&S staff, and operational staff, and conducted site visits to the East Jakarta facility in November 2024. 

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan